Barclays PLC Sells 17,807 Shares of Inogen Inc (NASDAQ:INGN)
Barclays PLC cut its holdings in Inogen Inc (NASDAQ:INGN) by 29.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 42,314 shares of the medical technology company’s stock after selling 17,807 shares during the quarter. Barclays PLC’s holdings in Inogen were worth $2,029,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Advisor Group Inc. increased its stake in shares of Inogen by 71.4% in the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after buying an additional 192 shares during the period. TRUE Private Wealth Advisors bought a new stake in Inogen during the 2nd quarter worth about $66,000. Synovus Financial Corp acquired a new position in Inogen during the 3rd quarter valued at about $77,000. Steward Partners Investment Advisory LLC lifted its position in Inogen by 16.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the medical technology company’s stock valued at $100,000 after purchasing an additional 300 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of Inogen by 2,688.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,402 shares of the medical technology company’s stock valued at $227,000 after purchasing an additional 3,280 shares during the last quarter.
A number of research firms recently weighed in on INGN. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Leerink Swann cut shares of Inogen from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 8th. ValuEngine raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Inogen in a research report on Friday, November 22nd. Finally, Svb Leerink reissued a “market perform” rating and issued a $47.00 price target (down previously from $78.00) on shares of Inogen in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $82.00.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, November 5th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.08. Inogen had a net margin of 8.76% and a return on equity of 9.89%. The firm had revenue of $91.76 million during the quarter, compared to analysts’ expectations of $91.65 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities research analysts expect that Inogen Inc will post 1.11 earnings per share for the current year.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: Leveraged Buyout (LBO) Explained
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.